← Back to Search

Monoclonal Antibodies

Yttrium 90 glass microspheres TARE in combination with Durvalumab and Bevacizumab for Liver Cancer (EMERALD-Y90 Trial)

Phase 2
Recruiting
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time from first documented response until documented progression (approximately 3 years)
Awards & highlights

EMERALD-Y90 Trial Summary

"This trial aims to see how well a combination of durvalumab and bevacizumab given through an IV works in participants with liver cancer that cannot be removed through surgery, and who have

Who is the study for?
This trial is for adults with unresectable liver cancer (HCC) who can undergo TARE, have a Child-Pugh score class A (indicating good liver function), no cancer outside the liver, at least one measurable tumor in the liver, and are generally in good health or only mildly ill. They must also meet specific criteria for lung safety during treatment and have enough healthy liver tissue.Check my eligibility
What is being tested?
The study tests if combining Durvalumab (an IV drug) and Bevacizumab (another IV drug) after Transarterial Radioembolization (TARE using Yttrium 90 microspheres) improves outcomes for patients with HCC that cannot be surgically removed. The effectiveness and safety of this combination therapy are being evaluated.See study design
What are the potential side effects?
Potential side effects include those related to Durvalumab such as immune-related reactions affecting various organs, infusion reactions, fatigue; Bevacizumab may cause bleeding, high blood pressure; TARE could lead to abdominal pain or fever post-procedure.

EMERALD-Y90 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time from first documented response until documented progression (approximately 3 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and time from first documented response until documented progression (approximately 3 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival (PFS)
Secondary outcome measures
Duration of Response (DoR)
Number of participants with Adverse events (AEs)
Objective Response Rate (ORR)
+1 more

EMERALD-Y90 Trial Design

1Treatment groups
Experimental Treatment
Group I: Yttrium 90 glass microspheres TARE in combination with Durvalumab and BevacizumabExperimental Treatment3 Interventions
Participants will undergo Yttrium 90 glass microspheres TARE according to the dosimetry recommendation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
2017
Completed Phase 2
~3870
Bevacizumab
2013
Completed Phase 4
~5280

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,288 Previous Clinical Trials
288,620,051 Total Patients Enrolled
2 Trials studying Liver Cancer
1,040 Patients Enrolled for Liver Cancer
~67 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top